The decision most active patients reach first

For an athlete with a focal knee cartilage defect, the fork in the road looks deceptively simple: accept a quicker return to sport via bone-marrow stimulation, or invest in a longer recovery that offers substantially better odds of still competing five to ten years from now. That choice — not anatomy, not surgical technique — is what most active patients are really navigating.

Focal defects differ fundamentally from the diffuse joint-space loss seen in osteoarthritis. Because the damage is localised, restorative surgery is genuinely on the table; the goal is biological repair of the damaged surface, not replacement of the joint.

Microfracture was, for many years, the default first step for defects under 2 cm². It remained a reasonable option given the evidence available at the time. What subsequent cohort data have shown, however, is that the repair tissue it produces — fibrocartilage rather than true hyaline cartilage — degrades progressively under the repetitive loading of sport, typically within three to five years. This is a tissue-biology limitation, not a surgical failing.

Mosaicplasty addresses that limitation directly by placing living hyaline cartilage — bonded to its native bone base — into the defect. The structural difference between the two tissues is what drives the durability gap. The trade-off is a longer return-to-sport timeline, making this a deliberate, planned choice rather than a rapid-recovery shortcut.

What the procedure actually involves

Both OATS and mosaicplasty transfer osteochondral plugs — cylinders of living cartilage fused to their underlying bone — from a lower-load region of the patient's own knee into the damaged site. The terms are often used interchangeably, but they describe technically distinct variants. Single-plug OATS typically addresses defects in the 1–2 cm² range; mosaicplasty tiles several smaller plugs in a mosaic arrangement to cover larger defects, up to approximately 4 cm².

The harvest site is usually the periphery of the femoral condyle or the trochlear groove — areas that bear relatively little load during everyday movement. Each plug is cylindrical and sized precisely to fit a matching socket drilled into the defect. Once press-fitted into place, the bone component of the plug bonds with the recipient subchondral bone, while the cartilage surface — which is true hyaline cartilage, not a laboratory-grown substitute — becomes the new bearing surface.

Critically, the full osteochondral unit is transferred intact: cartilage and bone arrive together, preserving the calcified cartilage layer and structural interface that give the surface its load-bearing properties. The procedure is completed in a single operation — either arthroscopically or through a small open incision — with no requirement for cell culture or a second surgical stage.

The tissue biology behind long-term durability

The reason the two operations produce such different long-term results lies in what each one actually places into the defect.

Microfracture perforates the subchondral bone plate to access the marrow cavity beneath. Marrow-derived stem cells flood the lesion, forming a fibrin clot that gradually organises into repair tissue. That tissue is fibrocartilage — dominated by type I collagen, the structural protein found in tendons and scar. Type I collagen resists tension reasonably well but performs poorly under the compressive and shear forces generated by running, cutting, and jumping. Fibrocartilage also lacks the proteoglycan density of native cartilage, so it cannot distribute load evenly across the joint surface; under repetitive athletic demand, it abrades and progressively breaks down — a pattern consistently observed across athlete cohort studies.

Native hyaline cartilage is built around type II collagen — a matrix engineered specifically for compression. It is arranged in distinct structural zones, each calibrated to handle a different component of mechanical load; together they manage force transfer in a way fibrocartilage cannot replicate. When an osteochondral plug is transferred via OATS, this full zonal architecture arrives intact, together with the subchondral bone base that governs how forces travel from the cartilage surface into the underlying skeleton. As the transplanted bone integrates with the recipient bed, the entire osteochondral column reconstitutes — not merely the visible surface layer.

This is why the durability gap holds: it reflects a categorical difference in tissue mechanics rather than a product of different patient cohorts or surgical settings.

What 5–10 year evidence shows in competitive athletes

The headline numbers come from soccer — one of the most physically demanding cohort proxies available. In competitive players who underwent cartilage repair, 83% returned to play and 80% did so at the same competitive level they had held before injury. More tellingly, 87–100% maintained the ability to play sport at five years postoperatively. These figures are drawn from the 2021 Cartilage Book, which synthesises case series and systematic reviews rather than prospective randomised controlled trials — a design limitation worth stating plainly. Observational data can be confounded by patient selection, surgical variation, and follow-up attrition; it does not carry the evidentiary weight of an RCT. Consistent findings across multiple independent cohorts nonetheless carry meaningful signal, particularly when the observed outcome aligns so closely with the tissue-biological mechanism.

At the ten-year horizon, the comparative picture sharpens. The Gudas 2012 study — frequently cited as the longest head-to-head follow-up in this field — tracked young athletes randomised to OATS or microfracture and found substantially better outcomes in the OATS group at a decade post-surgery, with the microfracture cohort showing a clear trajectory of decline. This mirrors the broader pattern: mosaicplasty results prove more durable over the 5–10 year window, while microfracture outcomes demonstrably deteriorate across the same period.

One consistent tradeoff runs through this evidence base. Return to prior sports level takes considerably longer after mosaicplasty than after microfracture — a direct consequence of the osseous integration demands described in the preceding section, not a marker of complication. Patients who accept that extended timeline are, in effect, trading short-term availability for the structural durability that the five- and ten-year data reflect.

Who gets the best results — and who may not

Two factors stand out from the evidence as the strongest independent predictors of returning to the same level of sport after mosaicplasty: age under 25 and a defect smaller than 2 cm². These are starting points for a clinical conversation, not binary gates — but they do define the patient profile where results are most reliably strong.

The ideal candidate is a skeletally mature young athlete with a focal, full-thickness defect (ICRS grade III–IV) affecting the femoral condyle or trochlea, no diffuse articular damage elsewhere in the joint, and sufficient donor-site cartilage available for harvest. Defects up to approximately 4 cm² can be addressed using a mosaic of multiple plugs; beyond that threshold, autograft supply typically runs out.

Donor-site morbidity — the potential for discomfort or functional change at the harvest region — is a real clinical consideration. Available evidence does not quantify its incidence precisely, and the severity varies between patients; a frank pre-operative discussion about this tradeoff is part of any honest consent process.

When a defect exceeds what autograft can cover, osteochondral allograft (OCA) transplantation is the logical step-up. Published series report return-to-sport rates of 75–82%, but those figures come from only 3 of 13 available studies, most outcome data extend to fewer than three years, and reoperation rates range from 34% to 53% — a meaningful uncertainty that should inform shared decision-making rather than being glossed over.

At the other end of the spectrum, diffuse or advanced osteoarthritis falls outside the scope of cartilage restoration. OATS targets focal lesions in an otherwise reasonably preserved joint; where degeneration is widespread, cartilage repair is unlikely to alter the disease trajectory and a different pathway — alignment correction, joint preservation, or eventual replacement — becomes the appropriate discussion.

Recovery expectations and next steps at LCC

Planning for a successful outcome begins well before the operating list. Because osseous plug integration takes time, the return-to-sport timeline after mosaicplasty is measurably longer than after microfracture — typically several months of protected weight-bearing, progressive loading, and sport-specific rehabilitation before full training resumes. Integration is confirmed through clinical assessment and imaging rather than by elapsed time alone; the pace of progression follows biology, not a calendar.

That extended timeline is a clinical reality worth factoring in from the outset, not a reason to choose a procedure with weaker long-term results. Athletes who plan around it — accounting for pre-season schedules, contract timescales, and sport demands — tend to approach rehabilitation more consistently.

Assessment is as consequential as the surgery itself. Defect mapping, lesion size, patient age, activity level, and donor-site availability all shape whether mosaicplasty is the right option or whether a different approach would serve better. At the London Cartilage Clinic on Harley Street, Professor Paul Y. F. Lee leads cartilage assessment and surgical planning for athletes considering this pathway.

Patients wishing to explore their options can arrange a consultation at londoncartilage.com.

1. [1] Microfracture surgery — Wikipedia. https://en.wikipedia.org/?curid=8840994 https://en.wikipedia.org/?curid=8840994
2. [2] Osteochondritis dissecans — Wikipedia. https://en.wikipedia.org/?curid=3762029 https://en.wikipedia.org/?curid=3762029